Outcomes of Direct Oral Anticoagulants Co-Prescribed with Common Interacting Medications

We examined the prevalence of co-prescription of DOACs with interacting medications and its impact on outcomes in patients with atrial fibrillation (AF). Patients with AF treated with a DOAC from 2010 to 2017 at the Mayo Clinic and co-prescribed medications that are inhibitors or inducers of the P-glycoprotein and/or Cytochrome P450 3A4 pathways were identified. The outcomes of stroke, transient ischemic attack, or systemic embolism, major bleeding, and minor bleeds were compared between patients with and without an enzyme inducer.

Source: The American Journal of Cardiology - October 27, 2021 Category: Cardiology Authors: David Sanborn, Alan Sugrue, Mustapha Amin, Ramila Mehta, Medhat Farwati, Abhishek J. Deshmukh, Haarini Sridhar, Azza Ahmed, Samuel J. Asirvatham, Narith N. Ou, Peter A. Noseworthy, Ammar M. Killu, Siva K. Mulpuru, Malini Madhavan Source Type: research